PE20120327A1 - Composicion adsorbente de fosfato a base de calcio, magnesio y hierro - Google Patents
Composicion adsorbente de fosfato a base de calcio, magnesio y hierroInfo
- Publication number
- PE20120327A1 PE20120327A1 PE2011001569A PE2011001569A PE20120327A1 PE 20120327 A1 PE20120327 A1 PE 20120327A1 PE 2011001569 A PE2011001569 A PE 2011001569A PE 2011001569 A PE2011001569 A PE 2011001569A PE 20120327 A1 PE20120327 A1 PE 20120327A1
- Authority
- PE
- Peru
- Prior art keywords
- iron
- calcium
- magnesium
- iii
- composition
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 5
- 229910052791 calcium Inorganic materials 0.000 title abstract 5
- 239000011575 calcium Substances 0.000 title abstract 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title abstract 3
- 229910052749 magnesium Inorganic materials 0.000 title abstract 3
- 239000011777 magnesium Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229910019142 PO4 Inorganic materials 0.000 title abstract 2
- 229910052742 iron Inorganic materials 0.000 title abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 2
- 239000010452 phosphate Substances 0.000 title abstract 2
- 239000003463 adsorbent Substances 0.000 title 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 3
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 abstract 2
- 229940088594 vitamin Drugs 0.000 abstract 2
- 229930003231 vitamin Natural products 0.000 abstract 2
- 235000013343 vitamin Nutrition 0.000 abstract 2
- 239000011782 vitamin Substances 0.000 abstract 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 2
- -1 CYSTEIN Chemical class 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 abstract 1
- 150000002213 flavones Chemical class 0.000 abstract 1
- 235000011949 flavones Nutrition 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 1
- 235000003969 glutathione Nutrition 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 abstract 1
- 230000000322 hemodialysis Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 201000005991 hyperphosphatemia Diseases 0.000 abstract 1
- 159000000014 iron salts Chemical class 0.000 abstract 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE SALES DE CALCIO, MAGNESIO Y HIERRO, DONDE LAS SALES DE CALCIO Y MAGNESIO SE SELECCIONAN DE CARBONATOS, CARBONATOS DE HIDROGENO, CARBONATOS BASICOS, ACETATOS, OXIDOS, HIDROXIDOS, MEZCLAS DE LOS MISMOS Y LA SAL DE HIERRO SE SELECCIONA DE OXIDO DE HIERRO (III), HIDROXIDO DE HIERRO (III), OXIHIDROXIDO DE HIERRO (III) Y FORMAS ESTABILIZADAS DE LAS MISMAS. LA COMPOSICION TAMBIEN COMPRENDE UNA SUSTANCIA ADICIONAL FARMACEUTICAMENTE ACTIVA TAL COMO VITAMINA D, ANTIOXIDANTES TAL COMO VITAMINA E, AMINOACIDOS TAL COMO CISTEINA, PEPTIDOS TAL COMO GLUTATION, FLAVONAS, Y/O FLAVONOIDES; LA RELACION MOLAR DE CALCIO A MAGNESIO ES DE 1:0.02-10; LA RELACION MOLAR DE CALCIO A HIERRO ES DE 1:0.02-20. DICHA COMPOSICION TIENE LA CAPACIDAD DE ADSORBER FOSFATO POR LO QUE ES UTIL EN EL TRATAMIENTO DE PACIENTES CON HEMODIALISIS, HIPERFOSFATEMIA Y ENFERMEDAD RENAL CRONICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09154107 | 2009-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120327A1 true PE20120327A1 (es) | 2012-04-11 |
Family
ID=40627528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001569A PE20120327A1 (es) | 2009-03-02 | 2010-03-01 | Composicion adsorbente de fosfato a base de calcio, magnesio y hierro |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20120052135A1 (es) |
| EP (1) | EP2403506A1 (es) |
| JP (1) | JP2012519201A (es) |
| KR (1) | KR101497003B1 (es) |
| CN (1) | CN102341111A (es) |
| AR (1) | AR076070A1 (es) |
| AU (1) | AU2010220396B2 (es) |
| BR (1) | BRPI1009110A2 (es) |
| CA (1) | CA2753364A1 (es) |
| CL (1) | CL2011002130A1 (es) |
| IL (1) | IL214509A0 (es) |
| MX (1) | MX2011009144A (es) |
| MY (1) | MY162484A (es) |
| NZ (1) | NZ594730A (es) |
| PE (1) | PE20120327A1 (es) |
| RU (1) | RU2527682C2 (es) |
| SG (1) | SG173887A1 (es) |
| TW (1) | TWI454267B (es) |
| WO (1) | WO2010100112A1 (es) |
| ZA (1) | ZA201106305B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| EP2548562A1 (de) | 2011-07-18 | 2013-01-23 | SeBo GmbH | Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern |
| JP6417339B2 (ja) * | 2013-03-08 | 2018-11-07 | ヴィダシム・インコーポレーテッド | 金属イオン−機能性繊維成分錯体組成物、その調製および使用 |
| EP2805603B1 (de) * | 2013-05-22 | 2017-01-11 | CLAAS E-Systems KGaA mbH & Co KG | Vorrichtung und Verfahren zur Überwachung der Schneidenschärfe |
| WO2015181205A1 (en) | 2014-05-28 | 2015-12-03 | Biaqua B.V. | Method for removing phosphate from water fractions |
| CN105232767A (zh) * | 2015-09-29 | 2016-01-13 | 江苏锦宇环境工程有限公司 | 一种制备吸附磷酸盐的药物制剂的方法 |
| CN107397760B (zh) * | 2016-05-19 | 2021-07-30 | 欣凯医药化工中间体（上海）有限公司 | 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用 |
| CN107397758A (zh) * | 2016-05-19 | 2017-11-28 | 欣凯医药化工中间体（上海）有限公司 | 一种磷结合剂及其制备方法 |
| WO2018222865A1 (en) * | 2017-05-31 | 2018-12-06 | Mars, Incorporated | Methods of diagnosing and treating chronic kidney disease |
| CN119488480A (zh) | 2019-02-28 | 2025-02-21 | 雷尼布斯治疗公司 | 新型铁组合物及其制造和使用方法 |
| US20210130251A1 (en) * | 2019-07-17 | 2021-05-06 | Water Warriors Inc. | Adsorbent Structures for the Removal of Phosphates and Ammonia from Wastewater and Methods of Use |
| MX2021015590A (es) * | 2019-07-23 | 2022-03-02 | Nestle Sa | Metodos y composiciones con beneficios renales para felinos. |
| CN113029978A (zh) * | 2019-12-25 | 2021-06-25 | 远大生命科学(辽宁)有限公司 | 一种检测含镧试剂的磷结合能力的方法 |
| CN111905736B (zh) * | 2020-07-23 | 2021-10-26 | 安徽工业大学 | 一种半胱氨酸功能化改性的羟基氧化铁、电催化剂、制备方法及应用 |
| WO2025176793A1 (en) * | 2024-02-21 | 2025-08-28 | Mars, Incorporated | Food composition for treating mineral bone disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970079A (en) * | 1989-06-05 | 1990-11-13 | Purdue Research Foundation | Method and composition of oxy-iron compounds for treatment of hyperphosphatemia |
| DE19547356A1 (de) * | 1995-12-19 | 1997-06-26 | Vifor Int Ag | Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung |
| GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| DE19917705C1 (de) * | 1999-04-20 | 2000-12-28 | Vitasyn Gmbh | Mittel zur Therapie von Hyperphosphatämie |
| DE102004031181A1 (de) * | 2004-06-28 | 2006-01-19 | Vifor (International) Ag | Phosphatadsorbens |
| MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| EP1932808A1 (en) * | 2006-12-14 | 2008-06-18 | Novartis AG | Iron(III)-Carbohydrate based phosphate adsorbent |
-
2010
- 2010-03-01 CA CA2753364A patent/CA2753364A1/en not_active Abandoned
- 2010-03-01 EP EP10705883A patent/EP2403506A1/en not_active Withdrawn
- 2010-03-01 BR BRPI1009110A patent/BRPI1009110A2/pt not_active IP Right Cessation
- 2010-03-01 NZ NZ594730A patent/NZ594730A/xx not_active IP Right Cessation
- 2010-03-01 MX MX2011009144A patent/MX2011009144A/es unknown
- 2010-03-01 JP JP2011552406A patent/JP2012519201A/ja active Pending
- 2010-03-01 MY MYPI2011004105A patent/MY162484A/en unknown
- 2010-03-01 AU AU2010220396A patent/AU2010220396B2/en not_active Ceased
- 2010-03-01 AR ARP100100600A patent/AR076070A1/es not_active Application Discontinuation
- 2010-03-01 CN CN2010800106646A patent/CN102341111A/zh active Pending
- 2010-03-01 WO PCT/EP2010/052551 patent/WO2010100112A1/en not_active Ceased
- 2010-03-01 PE PE2011001569A patent/PE20120327A1/es not_active Application Discontinuation
- 2010-03-01 US US13/202,586 patent/US20120052135A1/en not_active Abandoned
- 2010-03-01 RU RU2011140017/15A patent/RU2527682C2/ru not_active IP Right Cessation
- 2010-03-01 KR KR20117023162A patent/KR101497003B1/ko not_active Expired - Fee Related
- 2010-03-01 SG SG2011062239A patent/SG173887A1/en unknown
- 2010-03-01 TW TW099105799A patent/TWI454267B/zh not_active IP Right Cessation
-
2011
- 2011-08-08 IL IL214509A patent/IL214509A0/en unknown
- 2011-08-26 ZA ZA2011/06305A patent/ZA201106305B/en unknown
- 2011-09-01 CL CL2011002130A patent/CL2011002130A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG173887A1 (en) | 2011-10-28 |
| KR101497003B1 (ko) | 2015-02-27 |
| EP2403506A1 (en) | 2012-01-11 |
| TWI454267B (zh) | 2014-10-01 |
| US20120052135A1 (en) | 2012-03-01 |
| WO2010100112A1 (en) | 2010-09-10 |
| JP2012519201A (ja) | 2012-08-23 |
| NZ594730A (en) | 2013-06-28 |
| CL2011002130A1 (es) | 2012-03-23 |
| ZA201106305B (en) | 2012-05-30 |
| RU2527682C2 (ru) | 2014-09-10 |
| MY162484A (en) | 2017-06-15 |
| TW201034677A (en) | 2010-10-01 |
| BRPI1009110A2 (pt) | 2019-09-24 |
| AR076070A1 (es) | 2011-05-18 |
| IL214509A0 (en) | 2011-09-27 |
| CA2753364A1 (en) | 2010-09-10 |
| CN102341111A (zh) | 2012-02-01 |
| AU2010220396B2 (en) | 2013-10-17 |
| RU2011140017A (ru) | 2013-04-10 |
| MX2011009144A (es) | 2011-09-15 |
| KR20110128329A (ko) | 2011-11-29 |
| AU2010220396A1 (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120327A1 (es) | Composicion adsorbente de fosfato a base de calcio, magnesio y hierro | |
| PE20081381A1 (es) | Adsorbente de fosfato basado en hierro iii | |
| ME01133B (me) | Kombinovana terapija sa peptidnim epoksiketonima | |
| TR201905480T4 (tr) | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. | |
| TNSN07452A1 (en) | Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
| UA105210C2 (ru) | Противораковая вакцина и ее применение | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| EA200801275A1 (ru) | Стабилизированные составы карбоната лантана | |
| WO2009101205A3 (en) | Immunogenic control of tumours and tumour cells | |
| PL1680128T3 (pl) | Heksafosforan mio-inozytolu do stosowania miejscowego | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| MX368363B (es) | Forma de dosificacion efervescente. | |
| UY27727A1 (es) | Nueva composicion farmacéutica- | |
| WO2008104852A3 (en) | Pharmaceutical compositions comprising adsorbate of fenofibrate | |
| AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
| DE602005016803D1 (de) | Zusammensetzungen mit strontium und vitamin d und ihre verwendungen | |
| UA104281C2 (ru) | Противоопухолевые аналоги пептидов, способ их получения и фармацевтическая композиция на них основе | |
| AR059577A1 (es) | Agente de aceleracion de absorcion del calcio | |
| EA200801274A1 (ru) | Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана | |
| HRP20100086T1 (hr) | (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL | |
| EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
| AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
| BRPI0810682A2 (pt) | agente antitumoral em especial para o tratamento de tumores dérmicos, fármaco, kit compreendendo fármaco. | |
| RU2004135345A (ru) | Фармацевтическая композиция для профилактики и дополнительной химиотерапии туберкулеза | |
| WO2007116428A3 (en) | Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |